SAN DIEGO, Oct. 9, 2020 /PRNewswire/ -- Arena
Pharmaceuticals, Inc. (Nasdaq: ARNA) will present new data
from the Phase 2 OASIS trial and its open-label extension for its
investigative drug candidate etrasimod, a next-generation,
once-daily, oral, highly selective sphingosine 1-phosphate (S1P)
receptor modulator, in patients with moderately to severely active
ulcerative colitis (UC) at the 26th Annual United European
Gastroenterology (UEG) Week. Arena will also present preclinical
data for olorinab, a peripherally acting, highly selective, full
agonist of the cannabinoid receptor 2 (CB2), in
development for the treatment of visceral pain in gastrointestinal
(GI) diseases. UEG Week is taking place virtually October 11-13, 2020.
Arena Sponsored Symposium Details:
Title: Opening the Door to Emerging Investigational
Treatments in Ulcerative Colitis: What Awaits Us?
Intended Audience: This symposium is designed for
non-US healthcare professionals and is not affiliated with UEGW
Speakers: William Sandborn, MD (Chair), Professor
Silvio Danese, Remo Panaccione, MD, FRCPC
Day/Time: Monday, October 12 at 17:30 CET
Presentation Details:
Title: Early and
Durable Symptom Control in Patients with Moderately to Severely
Active Ulcerative Colitis Treated with Etrasimod in the Randomised,
Double Blind, Placebo Controlled, Phase 2 OASIS Trial and Open
Label Extension
Day/Time: Tuesday, October 13,
2020, from 15:00-16:00 CET
ePoster: P0481
Title: Expression of Cannabinoid Receptors and
the Effect of Olorinab, a Peripherally Acting, Highly Selective,
Full Agonist of the Cannabinoid Receptor 2, on Visceral
Hypersensitivity in Rodent Models of Irritable Bowel Syndrome and
Inflammatory Bowel Disease
Day/Time: Sunday, October 11, 2020, 18:00-19:00
CET
Oral presentation: OP058
Title: The Incremental Increasing Rate of
Thromboembolic Events in Patients with Inflammatory Bowel Disease
Compared to Patients Without Autoimmune
Disorder
Event: Virtual poster
exhibition
ePoster: P0377
About Etrasimod
Etrasimod (APD334) is a once-daily,
oral, highly selective sphingosine 1-phosphate (S1P) receptor
modulator, discovered by Arena, designed to provide systemic and
local cell modulation by targeting S1P receptor subtypes 1, 4 and
5. Etrasimod has therapeutic potential in immune and
inflammatory-mediated diseases such as ulcerative colitis, Crohn's
disease, and atopic dermatitis. S1P receptors have been
demonstrated to be involved in the modulation of several biological
responses, including lymphocyte trafficking from lymph nodes to the
peripheral blood. By isolating subpopulations of lymphocytes in
lymph nodes, fewer immune cells are available in the circulating
blood to effect tissue damage.
About Olorinab
Olorinab (APD371) is an oral,
peripherally acting, highly selective, full agonist of the
cannabinoid type 2 receptor (CB2). Olorinab is an
internally discovered investigational drug candidate that Arena is
exploring for development in several indications, with an initial
focus on visceral pain in gastrointestinal disorders. This
compound, through its selectivity for CB2, versus the
cannabinoid type 1 receptor (CB1), was designed to
provide pain relief while minimizing the risk of psychoactive
adverse effects.
Etrasimod and olorinab are investigational compounds that are
not approved for any use in any country.
About Arena Pharmaceuticals
ARENA
Pharmaceuticals is a team with a singular purpose – deliver
our important medicines to patients.
In a rapidly changing global market, we work with a sense of
urgency every day to understand the needs of all our stakeholders,
identify bold, sometimes disruptive, ideas to get our medicines to
patients, and relentlessly execute until it's done.
ARENA - Care More. Act Differently.
Forward-Looking Statements
Certain statements in this
press release are forward-looking statements that involve a number
of risks and uncertainties. Such forward-looking statements include
statements about Arena's participation in UEG Week, including its
symposium, and data presentations; the opportunity, development and
potential of etrasimod and olorinab; and Arena's purpose, work,
understanding, ideas, and execution. For such statements, Arena
claims the protection of the Private Securities Litigation Reform
Act of 1995. Actual events or results may differ materially from
Arena's expectations. Factors that could cause actual results to
differ materially from the forward-looking statements include those
disclosed in Arena's filings with the Securities and Exchange
Commission. These forward-looking statements represent Arena's
judgment as of the time of this release. Arena disclaims any intent
or obligation to update these forward-looking statements, other
than as may be required under applicable law.
Corporate Contact:
Megan E. Knight
Arena Pharmaceuticals, Inc.
Director, Investor Relations
mknight@arenapharm.com
858.210.3635
Arena Media Contact:
IR@arenapharm.com
858.453.7200
View original content to download
multimedia:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-presence-at-united-european-gastroenterology-week-strengthens-ongoing-commitment-to-the-gastrointestinal-disease-community-301149612.html
SOURCE Arena Pharmaceuticals, Inc.